540-1385 West 8th Avenue
Member Sector: Biopharmaceuticals
Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetricâ„¢ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. The company’s novel Azymetricâ„¢ and AlbuCOREâ„¢ platforms, and its proprietary ZymeCADâ„¢ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. More information on Zymeworks can be found at www.zymeworks.com.